[Therapeutic Options in Vitreomacular Traction With or Without a Macular Hole].

Treatment is usually indicated for symptomatic vitreomacular traction (VMT) with or without a full thickness macular hole (FTMH) and without spontaneous resolution. Ultrastructural parameters are evaluated by SD-OCT, in order to classify the vitreoretinal interface and to estimate the success rate of treatment. The resolution rate after therapy with intravitreal Jetrea® (Ocriplasmin) is high (up to 70 %) in patients with symptomatic focal vitreomacular traction (≤ 1500 µm) with or without a macular hole (≤ 250 µm) and with no epiretinal membrane (ERM), but depends on the exact baseline analysis. All other patients with idiopathic traction retinopathy should be treated by minimal invasive pars plana vitrectomy (MIVI). Vitreoretinal surgery effectively removes traction and gives a high closure rate of a full thickness macular hole (FTMH, 90 to 100 %). It is now a very safe procedure with few side effects. Despite a low risk profile (cataract, retinal tear etc.) the indication for surgery needs to take the safety profile into account. Therefore vitrectomy is only indicated in symptomatic patients complaining of blurred vision, VA reduction and metamorphopsia. Vitrectomy is also indicated in patients whose treatment by pharmacologic vitreolysis has failed.

[1]  M. Maier,et al.  [Ocriplasmin as a treatment option for symptomatic vitreomacular traction with and without macular hole. First clinical experiences]. , 2015, Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft.

[2]  Jose A. Martinez,et al.  Intravitreal gas injection for the treatment of vitreomacular traction syndrome , 2015 .

[3]  R. Avery,et al.  Intravitreal Perfluoropropane Gas (C3F8) Versus Ocriplasmin for Vitreomacular Traction (VMT) , 2015 .

[4]  Abigail T Fahim,et al.  Acute ocriplasmin retinopathy. , 2015, Retina.

[5]  Benjamin Reiss,et al.  TRANSIENT VISION LOSS AFTER OCRIPLASMIN INJECTION , 2015, Retina.

[6]  J. Ruiz-Moreno,et al.  A Review of Current Management of Vitreomacular Traction and Macular Hole , 2015, Journal of ophthalmology.

[7]  A. Joussen,et al.  Does ocriplasmin affect the RPE–photoreceptor adhesion in macular holes? , 2014, British Journal of Ophthalmology.

[8]  K. Bartz-Schmidt,et al.  Rate and timing of spontaneous resolution in a vitreomacular traction group: Should the role of watchful waiting be re-evaluated as an alternative to Ocriplasmin therapy? , 2014, British Journal of Ophthalmology.

[9]  M. Humayun,et al.  Profile of ocriplasmin and its potential in the treatment of vitreomacular adhesion , 2014, Clinical ophthalmology.

[10]  P. Stalmans,et al.  A RETROSPECTIVE COHORT STUDY IN PATIENTS WITH DISEASES OF THE VITREOMACULAR INTERFACE (ReCoViT) , 2014 .

[11]  N. Bornfeld,et al.  Erste klinische Erfahrungen bei der Behandlung von vitreomakulären Traktionen mit Ocriplasmin , 2014, Klin Monatsbl Augenheilkd.

[12]  Judy E. Kim.  Safety and complications of ocriplasmin: ocriplasmin, ocriplasmin; oh, how safe art thou? , 2014, JAMA ophthalmology.

[13]  E. Reichel,et al.  Vision loss after intravitreal ocriplasmin: correlation of spectral-domain optical coherence tomography and electroretinography. , 2014, JAMA ophthalmology.

[14]  Y. Morizane,et al.  Autologous transplantation of the internal limiting membrane for refractory macular holes. , 2014, American journal of ophthalmology.

[15]  N. Khan,et al.  Acute panretinal structural and functional abnormalities after intravitreous ocriplasmin injection. , 2014, JAMA ophthalmology.

[16]  H. Flynn,et al.  CLINICAL COURSE OF VITREOMACULAR ADHESION MANAGED BY INITIAL OBSERVATION , 2014, Retina.

[17]  Susanne Binder,et al.  The International Vitreomacular Traction Study Group classification of vitreomacular adhesion, traction, and macular hole. , 2013, Ophthalmology.

[18]  Peter Stalmans,et al.  OCT-BASED INTERPRETATION OF THE VITREOMACULAR INTERFACE AND INDICATIONS FOR PHARMACOLOGIC VITREOLYSIS , 2013, Retina.

[19]  D. Gabel,et al.  Dyes for Eyes™: Hydrodynamics, Biocompatibility and Efficacy of ‘Heavy' (Dual) Dyes for Chromovitrectomy , 2013, Ophthalmologica.

[20]  K. Freund,et al.  Correlation of transient vision loss with outer retinal disruption following intravitreal ocriplasmin , 2013, Eye.

[21]  S. Beatty,et al.  THE NATURAL HISTORY OF TRACTIONAL CYSTOID MACULAR EDEMA , 2012, Retina.

[22]  A. Kampik.  Pathology of epiretinal membrane, idiopathic macular hole, and vitreomacular traction syndrome. , 2012, Retina.

[23]  Mark W. Johnson,et al.  Emerging nonsurgical methods for the treatment of vitreomacular adhesion: a review , 2011, Clinical ophthalmology.

[24]  P. Kertes,et al.  Re-operation of idiopathic full-thickness macular holes after initial surgery with internal limiting membrane peel , 2011, British Journal of Ophthalmology.

[25]  Z. Michalewska,et al.  LONG-TERM EVALUATION OF VITREOMACULAR TRACTION DISORDER IN SPECTRAL-DOMAIN OPTICAL COHERENCE TOMOGRAPHY , 2011, Retina.

[26]  R. Adelman,et al.  Inverted internal limiting membrane flap technique for large macular holes. , 2010, Ophthalmology.

[27]  F. Folgar,et al.  Macular hole surgery prognostic success rates based on macular hole size. , 2012, Ophthalmic surgery, lasers & imaging : the official journal of the International Society for Imaging in the Eye.

[28]  George A. Williams,et al.  VITREOMACULAR TRACTION SYNDROME: Impact of Anatomical Configuration on Anatomical and Visual Outcomes , 2008, Retina.

[29]  K Bailey Freund,et al.  Three-dimensional evaluation of vitreomacular traction and epiretinal membrane using spectral-domain optical coherence tomography. , 2008, American journal of ophthalmology.

[30]  J. Sebag.  Anomalous posterior vitreous detachment: a unifying concept in vitreo-retinal disease , 2004, Graefe's Archive for Clinical and Experimental Ophthalmology.

[31]  C Haritoglou,et al.  Macular hole size as a prognostic factor in macular hole surgery , 2002, The British journal of ophthalmology.

[32]  E. Uchino,et al.  Initial stages of posterior vitreous detachment in healthy eyes of older persons evaluated by optical coherence tomography. , 2001, Archives of ophthalmology.

[33]  E. Uchino,et al.  Postsurgical evaluation of idiopathic vitreomacular traction syndrome by optical coherence tomography. , 2001, American journal of ophthalmology.

[34]  H. Schatz,et al.  Surgical results in the vitreomacular traction syndrome. , 1994, Ophthalmology.

[35]  R. Wendel,et al.  Vitreous surgery for idiopathic macular holes. Results of a pilot study. , 1991, Archives of ophthalmology.

[36]  J D Gass,et al.  Idiopathic senile macular hole. Its early stages and pathogenesis. , 1988, Archives of ophthalmology.

[37]  A. B. Reese,et al.  Vitreomacular traction syndrome confirmed histologically. , 1970, American journal of ophthalmology.

[38]  M. Maier,et al.  [Unclear retinopathy after intravitreal injection of ocriplasmin]. , 2016, Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft.

[39]  R. Avery,et al.  Severe acute vision loss, dyschromatopsia, and changes in the ellipsoid zone on sd-oct associated with intravitreal ocriplasmin injection. , 2015, Retinal cases & brief reports.

[40]  D. Berinstein,et al.  Treatment outcomes and spectral-domain optical coherence tomography findings of eyes with symptomatic vitreomacular adhesion treated with intravitreal ocriplasmin. , 2015, American journal of ophthalmology.

[41]  J. Sebag,et al.  III.B. Anomalous Posterior Vitreous Detachment and Vitreoschisis , 2014 .

[42]  B. Dlouhy,et al.  Enzymatic vitreolysis with ocriplasmin for vitreomacular traction and macular holes. , 2012, The New England journal of medicine.

[43]  A. Gandorfer,et al.  Pharmakologische Vitreolyse , 2010, Klinische Monatsblatter fur Augenheilkunde.

[44]  J. Sebag,et al.  Combined Spectral-Domain Optical Coherence Tomography/Scanning Laser Ophthalmoscopy Imaging of Vitreous and the Vitreo-Retinal Interface , 2010 .

[45]  Carmen A Puliafito,et al.  Anatomical outcomes of surgery for idiopathic macular hole as determined by optical coherence tomography. , 2002, Archives of ophthalmology.

[46]  A. Kampik,et al.  Indocyanine green-assisted peeling of the internal limiting membrane in macular hole surgery affects visual outcome: a clinicopathologic correlation. , 2002, American journal of ophthalmology.

[47]  J. Sebag.  Pharmacologic vitreolysis. , 1998, Retina.

[48]  T. Hikichi,et al.  Course of vitreomacular traction syndrome. , 1995, American journal of ophthalmology.